SCHEMBL21177873

SCHEMBL21177873

Cc1nccc(NC2CCC(Oc3cc(N4CCOCC4)cc4nc(C)nc(C)c34)CC2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 1/20 0.38
PDE10A Q9Y233 3/20 0.37
TBK1 Q9UHD2 4/20 0.37
IKBKE Q14164 3/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
SYK P43405 4/20 0.36
GPR6 P46095 1/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
JAK3 P52333 1/20 0.35
TTK P33981 1/20 0.35
CDK4 P11802 1/20 0.34
CCNA2 P20248 1/20 0.34
CCND1 P24385 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30823273 1.00 PIK3C3 (0.38) PIK3C3PDE10ATBK1IKBKECYP1A2
SCHEMBL21187365 1.00 PIK3C3 (0.38) PIK3C3PDE10ATBK1IKBKECYP1A2
SCHEMBL21187285 0.91 PIK3C3 (0.38) PIK3C3PDE10ATBK1IKBKECYP1A2
SCHEMBL21187333 0.87 PIK3C3 (0.39) PIK3C3PDE10ATBK1IKBKESYK
SCHEMBL30823279 0.87 PIK3C3 (0.39) PIK3C3PDE10ATBK1IKBKESYK
SCHEMBL28471538 0.87 PIK3C3 (0.39) PIK3C3PDE10ATBK1IKBKESYK
SCHEMBL16091613 0.86 PDE10A (0.38) PIK3C3PDE10ATBK1IKBKECYP1A2
SCHEMBL21279021 0.86 PDE10A (0.38) PIK3C3PDE10ATBK1IKBKECYP1A2
SCHEMBL17750560 0.85 PDE10A (0.38) PIK3C3PDE10ATBK1IKBKECYP1A2
SCHEMBL21187293 0.85 PIK3CD (0.37) PIK3C3PDE10ATBK1IKBKESYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12005127-B2 DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-06-11 US disclosed
CN-111757876-B DNA-PK inhibitors 沃泰克斯药物股份有限公司 2024-03-22 CN disclosed
EP-3740480-B1 DNA-PK INHIBITORS VERTEX PHARMA (US) 2024-03-06 EP disclosed
EP-3740480-A1 DNA-PK INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2020-11-25 EP disclosed
US-20200353101-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2020-11-12 US disclosed
WO-2019143678-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200353101-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK PIK3C3 1839/4885PDE10A 1271/4885TBK1 475/4885
US-12005127-B2 DNA-PK inhibitors POLK, DTYMK, DCK PIK3C3 1839/4885PDE10A 1271/4885TBK1 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.